Meet Isomorphic Labs, the Google spinoff that aims to cure you

In 2024, Demis Hassabiswon a Nobel Prize in chemistry for his work in predicting protein structures through his company, Isomorphic Labs. The lab, which broke off from Google's DeepMind in 2021, raised $600 million from investors in a new funding round led by Thrive Capital on Monday. The company did not disclose a valuation.

Isomorphic uses artificial intelligence to discover new drugs through its AlphaFold technology, which was at the center of Hassabis’s Nobel win last year. Ultimately, Hassabis wants to do something that’s not exactly simple: He’s vowed to “solve all disease with the help of AI.”

Isomorphic is already working with big pharmaceutical companies such as Eli Lilly and Novartis, inking deals with the two drugmakers last year worth $3 billion. It plans to use the new money to improve its AI tools and to move its drugs toward clinical testing.